Safety and efficacy of HepaSphere 50–100 μm in the treatment of hepatocellular carcinoma. Issue 4 (4th July 2017)

• Record Type: Journal Article
• Authors: Zurstrassen, Charles Edouard; Gireli, Luiz Paulo De Oliveira; Tyng, Chiang Jeng; Bitencourt, Almir Galvão Vieira; Guimarães, Marcos Duarte; Barbosa, Paula Nicole Vieira; Santos Cavalcante, Aline Cristine Barbosa; Matushita Junior, João Paulo; Amoedo, Mauricio Kauark; Coimbra, Felipe Jose; Alves, Rogério Camargo Pinheiro; Chojniak, Rubens
• Is Part Of: Minimally invasive therapy & allied technologies. Volume 26:Issue 4(2017)
• Page Start: 212
• Page End: 219
• Publication Date: 2017-07-04
• Subjects: Hepatocellular carcinoma -- transarterial chemoembolization -- HepaSphere -- doxorubicin; Endoscopy -- Periodicals; Interventional radiology -- Periodicals; Endoscopic surgery -- Periodicals; 617.05
• DOI: 10.1080/13645706.2017.1288142
• Languages: English
• ISSNs: 1364-5706

Abstract

Abstract: Aim: To evaluate the effects of HepaSphere 50–100 μm (Merit Medical) as a doxorubicin carrier and embolization agent for the treatment of hepatocellular carcinoma (HCC). Material and methods: A prospective analysis of 18 patients recruited from a national cancer center was conducted. This analysis evaluated the efficacy and safety of HepaSphere, as expressed by the treatment response rate (measured by the modified Response Evaluation Criteria in Solid Tumors, mRECIST) and by the prevalence of treatment-related adverse events, respectively. Results: The cohort was predominantly male, with a mean age of 69 years. The objective response rate (complete + partial response) was 53.3%. The variable most likely to be associated with objective response was Barcelona Clinic Liver Cancer (BCLC) staging. The most prevalent adverse events were nausea, vomiting and abdominal pain. Conclusion: HepaSphere chemoembolization yielded a substantial objective response rate with an acceptable toxicity profile and should be considered an option for HCC treatment.